Summary:
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group Study To Evaluate Safety, Tolerability And Pharmacodynamics of Pf-06835919 Administered Daily For 16 Weeks In Adults With Non-Alcoholic Fatty Liver Disease And Type 2 Diabetes Mellitus On Metformin
Qualified Participants Must:
• Have Type 2 Diabetes
• Age 18-70 years old
• Metformin monotherapy
Qualified Participants May Receive:
May receive compensation for Travel